ReviewBiomolecules2025
Nanocomposite Biomaterials for Tissue-Engineered Hernia Repair: A Review of Recent Advances.
Review in Biomolecules, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hernia repair is among the most frequent procedures in general surgery, traditionally performed with synthetic meshes such as polypropylene. While effective in reducing recurrence, these materials are biologically inert and often trigger chronic inflammation, fibrosis, pain, and impaired abdominal wall function, with a significant impact on long-term quality of life. A comprehensive literature search was conducted in PubMed, Web of Science, and Scopus databases, and relevant preclinical, clinical, and review articles were synthesized within a narrative review framework. Recent advances in tissue engineering propose a shift from passive reinforcement to regenerative strategies based on biomimetic scaffolds, nanomaterials, and nanocomposites that replicate the extracellular matrix, enhance cell integration, and provide controlled drug delivery. Nanotechnology enables localized release of anti-inflammatory, antimicrobial, and pro-angiogenic agents, while electrospun nanofibers and composite scaffolds improve strength and elasticity. In parallel, 3D printing allows for patient-specific implants with tailored architecture and regenerative potential. Although preclinical studies show encouraging results, clinical translation remains limited by cost, regulatory constraints, and long-term safety uncertainties. Overall, these innovations highlight a transition toward personalized and regenerative hernia repair, aiming to improve durability, function, and patient quality of life.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.